Company intelligence / Profile preview

Beijing Second Pharmaceutical Co., Ltd.

Ownership: Private
Development stage: Commercial

Overview

The company manufactures over a hundred active pharmaceutical ingredients and finished pharmaceuticals, with APIs mainly produced for export to more than 40 countries[3]. It was the first APIs manufacturer in China to get U.S. FDA approval for Sulfamethazine in 1984[2].

Modalities: Active pharmaceutical ingredients (APIs)finished pharmaceuticals
Industry: Biotech

Drug pipeline

1 asset

amlodipine besylate

Commercial

Indications: Cardiovascular disease

Beyond the preview

Go deeper on Beijing Second Pharmaceutical Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Second Pharmaceutical Co., Ltd..

Explore the full profile